The role of serotonin in the pathophysiology and treatment of schizophrenia

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 9, Issue 1, 1997, Pages 1-17

  Abi Dargham, Anissa ^a   Laruelle, Marc ^b   Aghajanian, George K ^b   Charney, Dennis ^b   Krystal, John ^b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; CLOZAPINE; DOPAMINE; HALOPERIDOL; RISPERIDONE; RITANSERIN; SEROTONIN; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

BRAIN TISSUE; CEREBROSPINAL FLUID; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

EID: 0031034035     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.9.1.1     Document Type: Review

References (243)

1. Gaddum JH: Drug antagonistic to 5-hydroxytryptamine, in Ciba Foundation Symposium on Hypertension, edited by Wolstenholme GW. Boston, Little, Brown, 1954, pp 75-77
2. Wooley DW, Shaw E: A biological and pharmacological suggestion about certain mental disorders. Proc Natl Acad Sci USA 1954; 40:228-231
3. Snyder SH: Catecholamines in the brain as mediator of amphetamine psychosis. Arch Gen Psychiatry 1972; 27:169-179
4. Kane J, Honigfeld G, Singer J, et al: Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988; 45:789-796
5. Meltzer HY: The mechanism of action of novel antipsychotic drugs. Schizophr Bull 1991; 17:263-286
6. Seeman P: Atypical neuroleptics: Role of multiple receptors, endogenous dopamine, and receptor linkage. Acta Psychiatr Scand 1990; 82:14-20
7. Marder SR, Meibach RC:Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151:825-835
8. Chouinard G, Jones B, Remington G, et al: A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13:25-40
9. Dahlström A, Fuxe K: Evidence for the existence of monoamine-containing neurons in the central-nervous system, I: Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol Scand 1964; 62:1-55
10. Azmitia EC, Segal M: Autoradiographic analysis of the differential ascending projection of the dorsal and median raphe nuclei in the rat. J Comp Neurol 1978; 179:641-668
11. Steinbusch HWM: Distribution of serotonin-immunoreactivity in the central nervous system of the rat-cell bodies and terminal. Neuroscience 1981; 6:557-618
12. Moore A, Halaris A: Hippocampal innervation by serotonin neurons of the midbrain raphe in the rat. J Comp Neurol 1975; 164:171-184
13. Geyer M, Puerto A, Dawsey W, et al: Histologic and enzymatic studies of the mesolimbic and mesostriatal serotonergic pathways. Brain Res 1976; 106:241-256
14. Herve D, Pickel VM, Joh TH, et al: Serotonin axon terminals in the ventral tegmental area of the rat: Fine structure and synaptic input to dopaminergic neurons. Brain Res 1987; 435:71-83
15. Dray A, Gonye T, Oakley N, et al: Evidence of the existence of a raphe projection to the substantia nigra in rat. Brain Res 1976; 113:45-57
16. Dray A, Davies J. Oakley NR, et al: The dorsal and medial raphe projections to the substantia nigra in the rat: Electrophysiological, biochemical and behavioural observations. Brain Res 1978; 151:431-442
17. Fibiger HC, Miller JJ: An anatomical and electrophysiological investigation of the serotonergic projection from the dorsal raphe nucleus to the substantia nigra in the rat. Neuroscience 1977; 2:975-987
18. Phillipson OT: Afferent projections to the ventral tegmental area of Tsai and interfascicular nucleus: A horseradish peroxydase study in the rat. J Comp Neurol 1979; 187:117-144
19. Bradley PB, Engel G, Fenuik W, et al: Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacol 1986; 6:563-576
20. Hoyer D, Clarke DE, Fozard JR, et al: International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin) [review]. Pharmacol Rev 1994; 46:157-203
21. Martin G, Humphrey P: Classification review: Receptors for 5-hydroxytryptamine: Current perspectives on classification and nomenclature. Neuropharmacology 1994; 33:261-273
22. Wright DE, Seroogy KB, Lundgren KH, et al: Comparative localization of serotonin, (1A), (1C) and (2) receptor subtype mRNAs in rat brain. J Comp Neurol 1995; 351:357-373
23. 1B recognition sites. Brain Res 1986; 376:85-96
24. Gaddum JH, Picarelli ZP: Two kinds of tryptamine receptor. British Journal of Pharmacology and Chemotherapy 1957; 12:323-328
25. 2 recognition sites. Brain Res 1986; 376:97-107
26. 3 receptors in rat brain using radioligand binding. Nature 1987; 330:746-748
27. 3H]-LY278584 binding sites in human brain. J Neurochem 1992; 60:730-737
28. Shen Y, Monsma F Jr, Metcalf MA, et al: Molecular cloning and expression of a 5-hydroxytryptamine-7 serotonin receptor subtype. J Biol Chem 1993; 268:18200-18204
29. Roth BL, Craigo SC, Choudhary MS, et al: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994; 268:1403-1410
30. Monsma FJ Jr, Shen Y, Ward RP, et al: Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol 1993; 43:320-327
31. Rinkel M, Hyde R, Solomon H, et al: Experimental psychiatry II: Clinical and physio-chemical observations in experimental psychosis. Am J Psychiatry 1955; 111:881-895
32. Hollister LE: Drug-induced psychoses and schizophrenic reactions: A critical comparison. Ann NY Acad Sci 1962; 96:80-88
33. Freedman B, Chapman L: Early subjective experiences in schizophrenic episodes. J Abnorm Psychol 1973; 82:46-54
34. Murphy H, Wittkower E, Fried J, et al: Cross-cultural survey of schizophrenic symptomatology. International Journal of Social Psychiatry 1963; 9:237-249
35. Langs RJ, Barr HL: Lysergic acid diethylamide (LSD-25) and schizophrenic reactions. J Nerv Ment Dis 1968; 147:163-172
36. Fishman L: Dreams, hallucinogenic drug states and schizophrenia: A psychological and biological comparison. Schizophr Bull 1983; 9:73-94
37. Aghajanian GK: Serotonin and the action of LSD in the brain. Psychiatric Annals 1994; 24:137-141
38. 2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 1984; 35:2505-2511
39. 2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology 1988; 94:231-316
40. Stahl SM, Wets K: Indolamines and schizophrenia, in Handbook of Schizophrenia, vol 2: Neurochemistry and Neuropharmacology of Schizophrenia, edited by Henn FA, DeLisi LE. Amsterdam, Elsevier Science, 1987, pp 257-296
41. Bleich A, Brown S-L, Kahn R, et al: The role of serotonin in schizophrenia. Schizophr Bull 1988; 14:297-315
42. Ashcroft GW, Crawford TBB, Eccleston D, et al: 5-Hydroxyindole compounds in the cerebrospinal fluid of patients with psychiatric or neurological diseases. Lancet 1966; 2:1049-1052
43. Bowers MB Jr, Heninger GR, Gerbode F: Cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in psychiatric patients. International Journal of Neuropharmacology 1969; 8:255-262
44. Gomes UCR, Shanley BC, Potgieter L, et al: Noradrenergic overactivity in schizophrenia: Evidence based on cerebrospinal fluid noradrenaline and cyclic nucleotide concentrations. Br J Psychiatry 1980; 137:346-351
45. Wode-Helgodt B, Fyro B, Gillberg B, et al: Effect of chlorpromazine treatment on monoamine metabolite levels in cerebrospinal fluids on psychotic patients. Acta Psychiatr Scand 1977; 56:280-293
46. Persson T, Roos BE: Acid metabolites from monoamines in cerebrospinal fluid of chronic schizophrenics. Br J Psychiatry 1969; 115:95-98
47. Rimon R, Roos BE, Räkköläinen V, et al: The content of 5-hydroxy-indolacetic acid and homovanillic acid in the cerebrospinal fluid of patients with acute schizophrenia. J Psychosom Res 1971; 15:375-378
48. Post RM, Fink E, Carpenter WT, et al: Cerebrospinal fluid amine metabolites in acute schizophrenia. Arch Gen Psychiatry 1975; 32:1063-1069
49. Bowers MB Jr: Central dopamine turnover in schizophrenic syndromes. Arch Gen Psychiatry 1974; 31:50-54
50. Nybäck H, Berggren BM, Hindmarsh T, et al: Cerebroventricular size and monoamine metabolites in schizophrenic patients and healthy volunteers. Psychiatry Res 1983; 9:301-308
51. Potkin S, Weinberger DR, Linnoila M, et al: Low CSF 5-hydroxyindoleacetic acid in schizophrenic brains with enlarged ventricules. Am J Psychiatry 1983; 140:21-25
52. Losonczy MF, Song IS, Mohs RC, et al: Correlates of lateral ventricular size in chronic schizophrenia, II: Biological measures. Am J Psychiatry 1986; 143:1113-1118
53. Jennings WS, Schultz SC, Narasimhachar N, et al: Brain ventricular size and CSF monoamine metabolite in an adolescent inpatient population. Psychiatry Res 1984; 16:87-94
54. Pickar D, Roy A, Brieer A, et al: Suicide and aggression in schizophrenia: Neurobiologic correlates. Ann NY Acad Sci 1986; 189-196
55. Weinberger DR, Berman KF, Illowsky BP: Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia, III: A new cohort and evidence for a monoaminergic mechanism. Arch Gen Psychiatry 1988; 45:609-615
56. Widerlöv E: A critical appraisal of CSF monoamine metabolite studies in schizophrenia. Ann NY Acad Sci 1988; 537:309-323
57. Kahn RS, Davidson M, Knott P, et al: Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia: Serotonin-dopamine interactions as a target for treatment. Arch Gen Psychiatry 1993; 50:599-605
58. Winblad B, Bucht G, Gottfries CG, et al: Monoamines and monoamine metabolites in brains from demented schizophrenics. Acta Psychiatr Scand 1979; 60:17-28
59. Joseph MH, Baker HF, Crow TJ, et al: Brain tryptophan metabolism in schizophrenia: A post mortem study of metabolites on the serotonin and kynurenine pathways in schizophrenic and control subjects. Psychopharmacology 1979; 62:279-285
60. Crow TJ, Baker HF, Cross AJ, et al: Monoamine mechanisms in chronic schizophrenia: Post-mortem neurochemical findings. Br J Psychiatry 1979; 134:249-256
61. Farley IJ, Shannak KS, Hornykiewicz O: Brain monoamine changes in chronic paranoid schizophrenia and their possible relation to increased receptor sensitivity, in Receptors for Neurotransmitters and Peptides, edited by Pepeu G, Kuhar MJ, Enna SJ. New York, Raven, 1980, pp 427-133
62. Hansson LO, Waters N, Winblad B, et al: Evidence for biochemical heterogeneity in schizophrenia: A multivariate study of monoaminergic indices in human post-mortal brain tissue. J Neural Transm General Section 1994; 98:217-235
63. Laruelle M, Abi-Dargham A, Casanova MF, et al: Selective abnormalities of prefrontal serotonergic receptors in schizophrenia: A postmortem study. Arch Gen Psychiatry 1993; 50:810-818
64. Joyce JN, Shane A, Lexow N, et al: Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 1993; 8:315-336
65. Reference deleted.
66. Ohuoha D, Hyde T, Herman M, et al: Prefrontal serotonin receptor subtypes in schizophrenia and nonpsychotic suicides: An autoradiographic study. Arch Gen Psychiatry (in press)
67. Dean B, Opeskin K, Pavey G, et al: [H-3]paroxetine binding is altered in the hippocampus but not the frontal cortex or caudate nucleus from subjects with schizophrenia. J Neurochem 1995; 64:1197-1202
68. 3H]spiperidol. Mol Pharmacol 1979; 16:687-699
69. Bennett JP, Enna SJ, Bylund DB, et al: Neurotransmitter receptors in frontal cortex of schizophrenics. Arch Gen Psychiatry 1979; 36:927-934
70. Whitaker PM, Crow TJ, Ferrier IN: Tritiated LSD binding in frontal cortex in schizophrenia. Arch Gen Psychiatry 1981; 38:278-280
71. 2 receptor studies. Neuropsychopharmacology 1990; 3:361-369
72. 1c serotonin receptors. Mol Pharmacol 1992; 42:627-633
73. 2 receptors in chronic schizophrenics. Biol Psychiatry 1986; 21:1407-1414
74. 2) receptor binding in frontal cortex of schizophrenic patients. J Neural Transm 1991; 85:19-29
75. 2 receptors and their involvement in schizophrenia and neuroleptic drug action. J Neural Transm 1983; 18(suppl):273-277
76. 2-serotonergic receptors. Life Sci 1983; 33:2527-2533
77. 2 receptors in rat cerebral cortex. J Neurochem 1986; 46:191-197
78. 2 receptors in rat brain following chronic receptor blockade. J Receptor Res 1987; 7:223-239
79. Leysen J, Niemegeers C, Tollenaere J, et al: Serotonergic component of neuroleptic receptors. Nature 1978; 272:168-171
80. 3H-ligand for serotonin-2 receptor binding sites: Binding properties, brain distribution and functional role. Mol Pharmacol 1982; 21:301-314
81. 2 receptors of normal human brain in vitro. Eur J Pharmacol 1987; 143:279-282
82. 2 and β-adrenergic receptors in the brains of suicide victims. Arch Gen Psychiatry 1990; 47:1038-1047
83. 2 binding sites in the frontal cortex of suicide victims. Am J Psychiatry 1989; 146:730-736
84. 2 sites in cortex and amygdala. Brain Res 1993; 614:37-44
85. 2 and beta receptor in the frontal cortices of suicide victims. Arch Gen Psychiatry 1986; 43:954-959
86. Stanley M, Mann JJ: Increased serotonin-2 binding sites in frontal cortex of suicide victims. Lancet 1983; 2:214-216
87. 2 recep- tor binding sites in depressed suicide victims. Brain Res 1988; 443:272-280
88. Owen F, Chambers DR, Cooper SJ, et al: Serotonergic mechanisms in brain of suicide victims. Brain Res 1986; 362:185-188
89. 2 receptors in suicide victims: Violence of death, depression and effects of antidepressant treatment. Brain Res 1994; 642:281-289
90. 3H]ketanserin binding in the human brain postmortem: Effect of suicide. Brain Res 1990; 507:208-215
91. 2 receptors and suicide. Lancet 1983; 2:1256
92. 1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci 1991; 48:355-363
93. 3 receptors in schizophrenia: A postmortem study of the amygdala. Brain Res 1993; 616:53-57
94. 1 recognition sites. J Recept Res 1988; 8:59-81
95. Hamik A, Peroutka SJ: 1-(m-chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain. Biol Psychiatry 1989; 25:569-575
96. Kahn RS, Wetzler S: M-Chlorophenylpiperazine as a probe of serotonin function. Biol Psychiatry 1991; 30:1139-1166
97. 1c receptors. J Pharmacol Exp Ther 1987; 242:552-557
98. Wolf WA, Kuhn DM: The 5-HT transporter is an additional site of action for the 5-HT agonists RU 24969 and TFMPP. Neurochem Int 1993; 19:39-44
99. Seibyl JP, Krystal JH, Price LH, et al: Effects of ritanserin on the behavioral, neuroendocrine and cardiovascular response to m-chlorophenylpiperazine in healthy human subjects. Psychiatry Res 1991; 38:227-236
100. Iqbal N, Asnis GM, Wetzler S, et al: The MCPP challenge test in schizophrenia: Hormonal and behavioral responses. Biol Psychiatry 1991; 30:770-778
101. Krystal JH, Seibyl JP, Price LH, et al: M-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Arch Gen Psychiatry 1993; 50:624-635
102. Kahn RS, Siever LJ, Gabriel S, et al: Serotonin function in schizophrenia: Effects of metachlorophenylpiperazine in schizophrenic patients and healthy subjects. Psychiatry Res 1992; 43:1-12
103. Breier A, Kirkpatrick B, Buchanan RW: Clozapine attenuates metachlorophenylpiperazine (mCPP)-induced plasma cortisol increases in schizophrenia. Biol Psychiatry 1993; 34:492-494
104. Owen RR, Guttierrez-Esteinou R, Hsia J, et al: Effects of clozapine and fluphenazine treatment on response to m-chlorophenylpiperazine infusions in schizophrenia. Arch Gen Psychiatry 1993; 50:636-644
105. Lieberman JA, Kane JM, Alvir J: Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology 1987; 91:415-433
106. Wurtman RJ, Heft F, Melamed E: Precursor control of neurotransmitter synthesis. Pharmacol Rev 1981; 32:315-335
107. Lauer J, Inskip W, Bernshon J, et al: Observations on schizophrenic patients after iproniazid and tryptophan. Archives of Neurology and Psychiatry 1958; 80:122-130
108. Pollin W, Cardon PV, Kety SS: Effects of amino acid feedings in schizophrenic patients treated with iproniazid. Science 1961; 133:104-105
109. Bowers MB Jr: Cerebrospinal fluid 5-hydroxyindoles and behavior after L-tryptophan and pyridoxine administration to psychiatric patients. Neuropharmacology 1970; 9:599-604
110. Gillin J, Kaplan J, Wyatt R: Clinical effects of tryptophan in chronic schizophrenic patients. Biol Psychiatry 1976; 11:635-639
111. Chouinard G, Annable L, Young S, et al: A controlled study of tryptophan-benserazide in schizophrenia. Communications in Psychopharmacology 1978; 2:21-31
112. Morand C, Young S, Ervin F: Clinical response of agressive schizophrenics to oral tryptophan. Biol Psychiatry 1983; 18:575-578
113. Wyatt RJ, Vaughan T, Galanter M, et al: Behavioral changes of chronic schizophrenic patients given L-5-hydroxytryptophan. Science 1972; 177:1124-1126
114. Bigelow L, Walls P, Gillin J, et al: Clinical effects of L-5-hydroxytryptophan administration in chronic schizophrenic patients. Biol Psychiatry 1979; 14:53-67
115. van Praag HM, Lemus C, Kahn R: Hormonal probes of central serotonergic activity: Do they really exist? Biol Psychiatry 1987; 22:86-98
116. Casacchia M, Casati C, Fazio C: P-Chlorophenylalanine in schizophrenia. Biol Psychiatry 1975; 10:109-110
117. DeLisi L, Freed W, Gillin J, et al: P-Chlorophenylalanine trials in schizophrenic patients. Biol Psychiatry 1982; 11:471-477
118. Shore D, Korpi ER, Bigelow LB, et al: Fenfluramine and chronic schizophrenia. Biol Psychiatry 1985; 20:329-352
119. Stahl SM, Uhr SB, Berger PA: Pilot study on the effects of fenfluramine on negative symptoms in twelve schizophrenic patients. Biol Psychiatry 1985; 20:1098-1102
120. Soper HV, Elliott RO, Rejzer AA, et al: Effects of fenfluramine on neuropsychological and communicative functioning in treatment-refractory schizophrenia patients. J Clin Psychopharmacol 1990; 10:168-175
121. Seeman P, Lee T: Antipsychotic drugs: Direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975; 188:1217-1219
122. Creese I, Burt DR, Snyder SH: Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976; 19:481-483
123. Peroutka SJ, Snyder SS: Relationship of neuroleptic drug effects at brain dopamine, serotonin, α-adrenergic and histamine receptors to clinical potency. Am J Psychiatry 1980; 137:1518-1522
124. Baldessarini RJ, Frankenburg FR: Clozapine: A novel antipsychotic agent. N Engl J Med 1991; 324:746-754
125. Deutch A, Moghadam B, Innis R, et al: Mechanisms of action of atypical antipsychotic drugs: Implication for novel therapeutic strategies for schizophrenia. Schizophr Res 1991; 4:121-156
126. Lieberman JA: Understanding the mechanism of action of atypical antipsychotic drugs. Br J Psychiatry 1993; 163:7-18
127. 4. Neuropsychopharmacology 1992; 7:261-284
128. 1C sites. Eur J Pharmacol 1990; 191:93-96
129. Deutch AY, Lee MC, ladarola MJ: Regionally specific effects of atypical antipsychotic drugs on striatal fos expression: The nucleus accumbens shell as a locus of antipsychotic action. Mol Cell Neurosci 1992; 3:332-341
130. 2 receptors: An autoradiographic analysis in rat brain. Brain Res Bull 1986; 16:517-525
131. 4 receptor with high affinity for the antipsychotic clozapine. Nature 1991; 350:610-614
132. 2 binding affinity. Neuropsychopharmacol 1988; 1:101-107
133. Meltzer H: Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 1989; 99(suppl):S18-S27
134. Meltzer H, Matsubara S, Lee J: Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2, and serotonin2 pki values. J Pharmacol Exp Ther 1989; 251:238-246
135. Meco G, Bedini L, Bonifati V, et al: Risperidone in the treatment of chronic schizophrenia with tardive dyskinesia. Current Therapy Research 1989; 46:876-884
136. Mesotten F, Suy E, Pietquin M, et al: Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patients. Psychopharmacology 1989; 99:445-449
137. Claus A, Bollen J, DeCuyper H, et al: Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: A multicentre double-blind comparative study. Acta Psychiatr Scand 1992; 85:295-305
138. Hoyberg OJ, Fensbo C, Remvig J, et al: Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand 1993; 88:395-402
139. Gelders YG: Thymosthenic agents, a novel approach in the treatment of schizophrenia. Br J Psychiatry 1989; 155:33-36
140. 2 antagonist ritanserin in neuroleptic induced parkinsonism: A double blind comparison with orphenadrine and placebo. Clin Neuropharmacol 1990; 13:500-506
141. 2 antagonist ritanserin. Psychopharmacol Bull 1990; 26:373-376
142. Bleekers E, Goldfarb J, Green JP: Ritanserin in the treatment of negative symptoms in chronic schizophrenic patients. Collegium Internationale Neuro-psychopharmacologicum (CINP), Kyoto, Japan, 1990
143. Wiesel F-A, Nordstrom A-L, Farde L, et al: An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology 1994; 114:31-38
144. 2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: Behavioral, electrophysiological and neurochemical studies, J Pharmacol Exp Ther 1993; 266:684-691
145. Rossum V: The significance of dopamine receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther 1966; 160:492-494
146. Carlsson A, Lindqvist M: Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 1963; 20:140-144
147. Snyder SH: Amphetamine psychosis: A "model" schizophrenia mediated by catecholamines. Am J Psychiatry 1973; 130:61-67
148. Angrist B, van Kammen DP: CNS stimulants as a tool in the study of schizophrenia. Trends Neurosci 1984; 7:388-390
149. Hornykiewicz O: Dopamine deficiency and dopamine substitution in Parkinson's disease, in The Neurobiology of Dopamine Systems, edited by Winlow W, Markstein R. Manchester, UK, Manchester University Press; 1986; 312-328
150. Stevens J: An anatomy of schizophrenia? Arch Gen Psychiatry 1973; 29:177-189
151. Weinberger DR: Implications of the normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987; 44:660-669
152. Davis KL, Kahn RS, Ko G, et al: Dopamine in schizophrenia: A review and reconceptualization. Am J Psychiatry 1991; 148:1474-1486
153. Grace AA: Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia. Neuroscience 1991; 41:1-24
154. Kostowski W, Giacalone E, Garattini S, et al: Studies on behavioural and biochemical changes in rats after lesion of midbrain raphe. Eur J Pharmacol 1968; 4:371-376
155. Fibiger HC, Campbell BA: The effect of para-chlorophenylalanine on spontaneous locomotor activity in the rat. Neuropharmacology 1971; 10:25-32
156. Jacobs BL, Wise WD, Taylor KM: Differential behavioral and neuro- chemical effects following lesions of the dorsal or median raphe nuclei in rats. Brain Res 1974; 79:353-361
157. Jacobs BL, Trimbach C, Eubanks EE, et al: Hippocampal mediation of raphe lesion- and PCPA-induced hyperactivity in the rat. Brain Res 1975; 94:253-263
158. Geyer M, Puerto A, Menkes D, et al: Behavioral studies following lesions of the mesolimbic and mesostriatal serotonergic pathways. Brain Res 1976; 106:257-270
159. Mabry P, Campbell B: Serotonergic inhibition of catecholamine-induced behavioral arousal. Brain Res 1973; 49:381-391
160. Kelly PH, Seviour PW, Iversen SD: Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res 1975; 94:507-522
161. Neill D, Grant LD, Grossman SP: Selective potentiation of locomotor effects on amphetamine by midbrain raphe lesion. Physiol Behav 1972; 9:655-657
162. Lucki I, Harvey JA: Increased sensitivity to d- and l-amphetamine action after midbrain raphe lesions as measured by locomotor activity. Neuropharmacology 1979; 18:243-249
163. Costall B, Naylor RJ: Stereotyped and circling behaviour induced by dopaminergic agonists after lesions of the midbrain raphe nuclei. Eur J Pharmacol 1974; 29:206-222
164. Green TK, Harvey JA: Enhancement of amphetamine action after interruption of ascending serotonergic pathways. J Pharmacol Exp Ther 1974; 190:109-117
165. Segal D: Differential effects of para-chlorophenylalanine on amphetamine-induced locomotion and stereotypy. Brain Res 1976; 116:267-276
166. Breese GR, Cooper BR, Mueller RA: Evidence for involvement of 5-hydroxytryptamine in the actions of amphetamine. Br J Pharmacol 1974; 52:307-314
167. Hollister A, Breese G, Moreton Kuhn C, et al: An inhibitory role for brain serotonin-containing systems in the locomotor effects of d-amphetamine. J Pharmacol Exp Ther 1976; 198:12-22
168. Jacobs BL, Wise WD: Is there a catecholamine-serotonin interaction in the control of locomotor activity? Neuropharmacology 1975; 14:501-506
169. Neuburg J, Thut PD: Comparison of the locomotor stimulant mechanisms of action of d-amphetamine and d-amphetamine plus l-dopa: Possible involvement of serotonin. Biol Psychiatry 1974; 8:139-150
170. Grabowska ML, Antkiewicz L, Maj J, et al: Apomorphine and central serotonin neurons. Polish Journal of Pharmacology and Pharmacy 1973; 25:29-38
171. Baldessarini R, Amatruda T, Griffith F, et al: Differential effects of serotonin on turning and stereotypy induced by apomorphine. Brain Res 1975; 93:158-163
172. Costall B, Naylor R, Marsden C, et al: Serotoninergic modulation of the dopamine response from the nucleus accumbens. J Pharm Pharmacol 1976; 28:523-526
173. Fink H, Oelssner W: LSD, mescaline and serotonin injected into medial raphe nucleus potentiate apomorphine hypermotility. Eur J Pharmacol 1981; 75:289-296
174. Hadzovic S, Ernst AM: The effect of 5-hydroxytryptamine and 5-hydroxytryptophan on extra-pyramidal function. Eur J Pharmacol 1969; 6:90-95
175. Ungerstedt U, Butcher LL, Butcher SG, et al: Direct chemical stimulation of dopaminergic mechanisms in the neostriatum of the rat Brain Res 1969; 14:461-471
176. Ernst AM: Relationship of the central effect of dopamine on gnawing compulsion syndrome in rats and the release of serotonin. Archives Internationales de Pharmacodynamie 1972; 199:219-225
177. Rotrosen J, Angrist BM, Wallach MB, et al: Absence of serotonergic influence on apomorphine-induced stereotypy. Eur J Pharmacol 1972; 20:133-135
178. Pycock CJ: Turning behavior in animals. Neuroscience 1980; 5:461-514
179. Costall B, Naylor RJ, Marsden CD, et al: Circling behavior produced by asymmetric medial raphe lesions in rats. J Pharm Pharmacol 1976; 28:248-249
180. Giambalvo CT, Snodgrass ST: Biochemical and behavioral effects of serotonin neurotoxins on the nigro-striatal dopamine system: Comparison of injection sites. Brain Res 1978; 152:555-566
181. James TA, Starr MS: Rotational behaviour elicited by 5-HT in the rat: Evidence for an inhibitory role of 5-HT in the substantia nigra and corpus striatum. J Pharm Pharmacol 1980; 32:196-200
182. Nicolaou N, Garcia-Munoz M, Arbuthnott G, et al: Interactions between serotonergic and dopaminergic systems in rat brain demonstrated by small unilateral lesions of the raphe nuclei. Eur J Pharmacol 1979; 57:295-305
183. Tanner T: Circling behaviour in the rat following unilateral injections of p-chlorophenylalanine and ethanolamine-O-sulphate into the substantia nigra. J Pharm Pharmacol 1978; 30:158-161
184. Blackburn TP, Cox B, Heapy CG, et al: Supersensitvity of nigral serotonin receptor and rat rotational behavior. Eur J Pharmacol 1981; 71:343-346
185. Blackburn TP, Foster GA, Heapy CG, et al: Differential rotational behavior after unilateral 5-7-dihydroxytryptamine-induced lesion of the dorsal raphe nucleus. Br J Pharmacol 1979; 67:431-432
186. Jacobs BL, Trimbach C, Eubanks E, et al: Hippocampal mediation of raphe lesion and PCPA induced hyperactivity in the rat. Brain Res 1975; 94:253-261
187. Waddington JL, Crow TJ: Rotational responses to serotonergic and dopaminergic agonists after unilateral dihydroxytryptamine lesions of the medial forebrain bundle: Co-operative interaction of serotonin and dopamine in the neostriatum. Life Sci 1979; 25:1307-1314
188. De Simoni MG, Dal Toso G, Sokola A, et al: Modulation of striatal dopamine metabolism by the activity of dorsal raphe serotonergic afferences. Brain Res 1987; 411:81-88
189. Fog R: On stereotypy and catalepsy. Studies on the effect of amphetamine and neuroleptic in rats. Acta Neurol Scand 1972; 48(suppl 50):3-66
190. Kostowski W, Gumulka W, Czlonkowski A: Reduced cataleptogenic effects of some neuroleptics in rats with lesioned midbrain raphe and treated with p-chlorophenylalanine. Brain Res 1972; 48:443-446
191. Costall B, Fortune DH, Naylor RJ, et al: Serotonergic involvement with neuroleptic catalepsy. Neuropharmacology 1975; 14:859-868
192. Carter CJ, Pycock CJ: Possible importance of 5-hydroxytryptamine in neuroleptic-induced catalepsy in rats. Br J Pharmacol 1977; 60:267P
193. Waldmeier P, Delini-Srula A: Serotonin-dopamine interactions in the nigrostriatal system. Eur J Pharmacol 1979; 55:363-373
194. Carter C, Pycock C: A study of the site of interaction between dopamine and 5-hydroxytryptamine for the production of fluphenazine-induced catalepsy. Naunyn Schmiedebergs Arch Pharmacol 1978; 304:135-139
195. Hicks PB: The effect of serotonergic agents on haloperidol-induced catalepsy. Life Sci 1990; 47:1609-1615
196. Williams J, Davies JA: The involvement of 5-hydroxytryptamine in the release of dendritic dopamine from slices of substantia nigra. J Pharm Pharmacol 1983; 35:734-373
197. Nedergaard S, Bolam JP, Greenfield SA: Facilitation of a dendritic
198. 2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology 1989; 98:45-50
199. 2, antagonist, ritanserin, on biogenic amines in the rat nucleus accumbens. Eur J Pharmacol 1991; 192:427-429
200. 2 antagonist, in electrophysiological tests predictive of antipsychotic activity. J Pharmacol Exp Ther 1989; 249:673-680
201. 2A receptor antagonist, MDL 100,907, increases dopamine efflux in the prefrontal cortex of the rat. Eur J Pharmacol 1995; 273:273-279
202. Pehek EA, Meltzer HY, Yamamoto BK: The atypical antipsychotic drug amperozide enhances rat cortical and striatal dopamine efflux. Eur J Pharmacol 1983; 240:107-110
203. Pehek EA, Meltzer HY, Yamamoto BK: Local administration of ritanserin or ICS 205,930 enhances dopamine and serotonin efflux in rat prefrontal cortex. Society for Neuroscience Abstracts 1993; 19:302
204. Moghaddam B, Bunney BS: Acute Effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: An in vivo microdialysis study. J Neurochem 1990; 54:1755-1760
205. 2 receptor and alpha 1-adrenoceptor antagonism. J Clin Psychopharmacol 1995; 15:11S-18S
206. Svensson TH, Tung CS: Local cooling of pre-frontal cortex induces pace-maker-like firing of dopamine neurons in rat ventral tegumental area in vivo. Acta Physiol Scand 1989; 136:135-136
207. Allen RM, Young SJ: Phencyclidine-induced psychosis. Am J Psychiatry 1978; 135:1081-1084
208. Snyder S: Phencyclidine. Nature 1980; 285:355-356
209. 2 receptor antagonism. Schizophr Res 1993; 11:115P
210. 2 antagonist ritanserin blocks the effect of prefrontal cortex inactivation on rat A10 dopamine neurons in vivo. Acta Physiol Scand 1989; 136:497-498
211. Grenhoff J, Tung CS, Ugedo L, et al: Effects of amperozide, a putative antipsychotic drug, on rat midbrain dopamine neurons recorded in vivo. Pharmacol Toxicol 1990; Suppl 1:29-33
212. Bozarth MA: Neural basis of psychomotor stimulant and opiate reward: Evidence suggesting an involvement of a common dopaminergic system. Behav Brain Res 1986; 22:107-116
213. Nash JF: Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by in vivo microdialysis. Life Sci 1990; 47:2401-2408
214. Schmidt CJ, Sullivan CK, Fadayel GM: Blockade of striatal 5-hydroxytryptamine(2) receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine. J Neurochem 1994; 62:1382-1389
215. Bunney BS, Aghajanian GK: D-Amphetamine-induced inhibition of central dopaminergic neurons: Mediation by a striato-nigral feedback pathway. Science 1976; 192:391-393
216. Wang RY: Dopaminergic neurons in the rat ventral tegmental area, III: Effects of D- and L-amphetamine. Brain Res Rev 1981; 3:153-165
217. Butcher SP, Fairbrother IS, Kelly JS, et al: Amphetamine-induced dopamine release in rat striatum: An in vivo microdialysis study. J Neurochem 1988; 50:346-355
218. 2 mediated potentiation of dopamine synthesis and central serotonergic deficits. Eur J Pharmacol 1993; 238:291-296
219. 2A/2C receptor agonist, potentiates amphetamine-induced dopamine release in rat striatum. Brain Res 1995; 698:204-208
220. 2 receptors in schizophrenia and antipsychotic activity. Int Clin Psychopharmacol 1993; 8:25-32
221. Laruelle M, Abi-Dargham A, van Dyck CH, et al: Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug free schizophrenic subjects. Proc Natl Acad Sci USA 1996; 93:9235-9240
222. 2 receptors in interneurons. Synapse 1991; 9:208-218
223. German RL, Aghajanian GK: Pyramidal cells in piriform cortex receive a convergence of inputs from monoamine activated GABAergic interneurons. Brain Res 1993; 600:63-73
224. Marek GJ, Aghajanian GK: Excitation of interneurons in piriform cortex by 5-hydroxytryptamine: Blockade by MDL 100,907, a highly selective 5-HT(2A) receptor antagonist. Eur J Pharmacol 1994; 259:137-141
225. 2 receptors in the rat brain: Neurochemical identification of cell types by immunocytochemistry. Neuropsychopharmacology 1994; 11:157-166
226. Benes FM, McSparren J, Bird ED, et al: Deficits in small interneurons in schizophrenic cortex. Arch Gen Psychiatry 1991; 48:996-1001
227. Selemon LD, Rajkowska G, Goldman-Rakic PS: Cytologie abnormalities in area 9 of the schizophrenic cortex. Society for Neuroscience Abstracts 1993; 19:200
228. Pakkenberg B: Total nerve cell number in neocortex in chronic schizophrenics and controls estimated using optical disectors. Biol Psychiatry 1993; 34:768-772
229. Akbarian S, Kim JJ, Potkin SG, et al: Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry 1995; 52:258-266
230. Arnold SE, Lee VM, Gur RE, et al: Abnormal expression of two microtubule associated proteins (MAP2 and MAP5) in specific sub-fields of the hippocampal formation in schizophrenia. Proc Natl Acad Sci USA 1991; 88:10850-10854
231. Whitaker-Azmitia PM, Borella A, Raio N: Serotonin depletion in the adult rat causes loss of the dendritic marker MAP-2: A new animal model of schizophrenia? Neuropsychopharmacology 1995; 12:269-272
232. van Kammen DP, Murphy DL: Attenuation of the euphoriant and activating effects of d- and l-amphetamine by lithium carbonate treatment. Psychopharmacology (Bed) 1975; 44:215-224
233. 2 receptor activation in rats. Behav Neural Biol 1991; 55:214-226
234. 1c serotonin receptor levels: Methodology and mechanisms. Neuropsychopharmacology 190; 3:427-433
235. Conn PJ, Sanders-Bush E: Biochemical characterization of serotonin stimulated phosphoinositide turnover. Life Sci 1986; 38:663-669
236. Guan XM, McBride WJ: Serotonin microinfusion into the ventral tegmental area increases accumbens dopamine release. Brain Res Bull 1989; 23:541-547
237. Kalivas PW: Neurotransmitter regulation of dopamine neurons in the ventral tegumental area. Brain Res Rev 1993; 18:75-113
238. Crow TJ: Molecular pathology of schizophrenia: More than one disease process? British Medical Journal 1980; 280:66-68
239. Angrist B, Rotrosen J, Gershon S: Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia. Psychopharmacology 1980; 72:17-19
240. Tamminga CA, Schaffer MH, Smith RC, et al: Schizophrenic symptoms improve with apomorphine. Science 1978; 200:567-568
241. Grace AA: Cortical regulation of subcortical systems and its possible relevance to schizophrenia. J Neural Transm 1993; 91:111-134
242. Kapur S, Remington G: Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996; 153:466-76
243. Lamelle M, Abi-Dargham A, van Dyck CH, et al: SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 1995; 36:1182-1190